Signifor® LAR (pasireotide) – New indication
June 29, 2018 - The FDA approved Novartis’ Signifor LAR (pasireotide), for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Download PDF
